Dizhe Pharmaceutical: Voluntary Disclosure Notice on Schwarzhe\'s First-Line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR 20 Exon Insertion Mutation Obtaining CDE Breakthrough Treatment

SZSI · Oct 14

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

迪哲医药：自愿披露关于舒沃哲一线治疗EGFR 20号外显子插入突变的晚期非小细胞肺癌获得CDE突破性疗法认定的公告

Dizhe Pharmaceutical: Voluntary Disclosure Notice on Schwarzhe\'s First-Line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR 20 Exon Insertion Mutation Obtaining CDE Breakthrough Treatment

Risk Disclaimer

Statement